{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:19:10Z","timestamp":1793690350266,"version":"4.5.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Early evidence from studies outside of oncology has suggested that cannabidiol (CBD) may have anxiolytic effects without neuropsychiatric risks. An understanding of oral CBD in patients with cancer-related anxiety is urgently needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether a single 400-mg oral dose of a US Food and Drug Administration\u2013approved CBD improves clinical anxiety in an oncologic population.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase II, double-masked, placebo-controlled, randomized clinical trial was performed at the Dana-Farber Cancer Institute\u2019s Breast Oncology Center from November 2, 2021, through March 1, 2023. Women aged 18 years or older with advanced breast cancer and baseline clinical anxiety were included.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 1:1 to receive oral CBD, 400 mg, vs placebo within 48 hours before a scan assessing tumor burden.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was a between-arm comparison of change scores on the afraid subscale of the Visual Analog Mood Scale (VAMS) before and 2 to 4 hours after study drug ingestion. The VAMS scores were converted to T-scores to facilitate interpretation of mood change (&amp;gt;20 indicates a reliable change, &amp;gt;30 indicates both a reliable and clinically significant change). Exploratory outcomes included between-arm comparisons of anxiety levels 2 to 4 hours after study drug ingestion, between-arm comparisons of change scores on other VAMS subscales, and safety.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 50 participants, 25 were randomized to the placebo arm (mean [range] age, 57 [37-81] years) and 25 were randomized to the CBD arm (mean [range] age, 60 [30-79] years). The primary end point of VAMS afraid subscale change score, although numerically greater in the CBD arm, was not significantly different between arms (mean [SD]: CBD, \u221219.1 [15.4]; placebo, \u221215.0 [10.9];\n P<\/jats:italic>\n \u2009=\u2009.37). The secondary outcome directly comparing anxiety levels between arms 2 to 4 hours after study drug ingestion demonstrated significantly lower VAMS afraid T-scores for participants who received CBD compared with those receiving placebo (mean [SD]: CBD, 51.5 [12.8]; placebo, 58.0 [11.6];\n P<\/jats:italic>\n \u2009=\u2009.02). No grade 3 or 4 toxic effects were reported.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The findings of this randomized clinical trial show that CBD can be used safely in women with advanced breast cancer and clinical anxiety. Although the study did not meet its primary end point comparing preingestion vs postingestion anxiety change scores between study arms, anxiety levels in the CBD arm were significantly lower 2 to 4 hours after ingestion, suggesting a possible anxiolytic effect and warranting further investigation.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04482244<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.50391","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:32:12Z","timestamp":1734348732000},"page":"e2450391","source":"Crossref","is-referenced-by-count":12,"title":["Cannabidiol for Scan-Related Anxiety in Women With Advanced Breast Cancer"],"prefix":"10.1001","volume":"7","author":[{"given":"Manan M.","family":"Nayak","sequence":"first","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Emergency Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge"},{"name":"The Fenway Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Pirl","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Tulsky","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie C.","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Andrade","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Johns","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clint","family":"Vaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College at St Clare\u2019s and St Mary\u2019s Hospital, Denville, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana M.","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"2-3","key":"zoi241400r1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jad.2012.03.025","article-title":"Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age.","volume":"141","author":"Linden","year":"2012","journal-title":"J Affect Disord"},{"issue":"22","key":"zoi241400r2","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use.","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"zoi241400r3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003901","article-title":"Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates.","volume":"4","author":"Watts","year":"2014","journal-title":"BMJ Open"},{"issue":"11","key":"zoi241400r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-007618","article-title":"Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates.","volume":"5","author":"Watts","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"zoi241400r5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/neurolint13040059","article-title":"Benzodiazepines: uses, dangers, and clinical considerations.","volume":"13","author":"Edinoff","year":"2021","journal-title":"Neurol Int"},{"issue":"1","key":"zoi241400r6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.japh.2019.11.008","article-title":"Use of cannabidiol in anxiety and anxiety-related disorders.","volume":"60","author":"Skelley","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"5","key":"zoi241400r7","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/1097-0142(197911)44:5<1919::AID-CNCR2820440555>3.0.CO;2-T","article-title":"A survey of psychotropic drug prescriptions in an oncology population.","volume":"44","author":"Derogatis","year":"1979","journal-title":"Cancer"},{"issue":"6","key":"zoi241400r8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/JGO.2016.005728","article-title":"Applicability of the National Comprehensive Cancer Network\/Multinational Association of Supportive Care in Cancer guidelines for prevention and management of chemotherapy-induced nausea and vomiting in Southeast Asia: a consensus statement.","volume":"3","author":"Chan","year":"2017","journal-title":"J Glob Oncol"},{"issue":"2","key":"zoi241400r9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.npp.1300340","article-title":"Effects of cannabidiol (CBD) on regional cerebral blood flow.","volume":"29","author":"Crippa","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"zoi241400r10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life.","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front Pharmacol"},{"key":"zoi241400r11","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/026988119300700112","article-title":"Effects of ipsapirone and cannabidiol on human experimental anxiety.","volume":"7","author":"Zuardi","year":"1993","journal-title":"J Psychopharmacol"},{"issue":"1","key":"zoi241400r12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.","volume":"41","author":"Linares","year":"2019","journal-title":"Braz J Psychiatry"},{"issue":"6","key":"zoi241400r13","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/npp.2011.6","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients.","volume":"36","author":"Bergamaschi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"zoi241400r14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0269881110379283","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.","volume":"25","author":"Crippa","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"4","key":"zoi241400r15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders.","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"2","key":"zoi241400r16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/phar.1187","article-title":"The pharmacologic and clinical effects of medical cannabis.","volume":"33","author":"Borgelt","year":"2013","journal-title":"Pharmacotherapy"},{"key":"zoi241400r17","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1516-4446(12)70057-0","article-title":"Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.","volume":"34","author":"Schier","year":"2012","journal-title":"Braz J Psychiatry"},{"key":"zoi241400r18","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1002\/j.1552-4604.2002.tb05998.x","article-title":"Cannabidiol: an overview of some pharmacological aspects.","volume":"42","author":"Mechoulam","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"zoi241400r19","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.bbmt.2015.05.018","article-title":"Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: results of a phase II study.","volume":"21","author":"Yeshurun","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"zoi241400r20","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline.","volume":"42","author":"Braun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi241400r21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043215","article-title":"Scanxiety: a scoping review about scan-associated anxiety.","volume":"11","author":"Bui","year":"2021","journal-title":"BMJ Open"},{"issue":"10","key":"zoi241400r23","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7.","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"zoi241400r25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/02687039708248455","article-title":"Visual analogue mood scales to measure internal mood state in neurologically impaired patients: description and initial validity evidence.","volume":"11","author":"Stern","year":"1997","journal-title":"Aphasiology"},{"issue":"9","key":"zoi241400r27","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure.","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi241400r28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12904-019-0494-6","article-title":"Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).","volume":"18","author":"Good","year":"2019","journal-title":"BMC Palliat Care"},{"issue":"7","key":"zoi241400r29","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.22.01632","article-title":"Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD).","volume":"41","author":"Hardy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi241400r30","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1634\/theoncologist.2018-0536","article-title":"Randomized trial of a tailored cognitive-behavioral therapy mobile application for anxiety in patients with incurable cancer.","volume":"24","author":"Greer","year":"2019","journal-title":"Oncologist"},{"key":"zoi241400r24","volume-title":"VAMS: Visual Analog Mood Scales: Professional Manual","author":"Stern","year":"1997"},{"key":"zoi241400r22","unstructured":"Safety of CBD in humans\u2013a literature review. US Food and Drug Administration. Published December 12, 2019. Accessed November 1, 2024. https:\/\/www.fda.gov\/media\/152317\/download"},{"key":"zoi241400r26","unstructured":"Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Healthcare Delivery Research Program, National Cancer Institute. Accessed November 1, 2024. https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2828077\/nayak_2024_oi_241400_1733756408.2975.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T11:32:20Z","timestamp":1734348740000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2828077"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.50391","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}